XORTX Therapeutics Net Income

The latest net income for XRTX is $-3.9M as of June 2026. That compares with $-1.9M in the prior-year period — down 107.5% year over year. That is below the Materials sector average of $18B. Investors often review this figure alongside XORTX Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, XRTX's net income moved from $-1.9M to $-3.9M — a 107.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in XORTX Therapeutics's operating scale or balance-sheet position.

Against Materials companies, XRTX currently prints $-3.9M for net income, while the sector average sits near $18B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at XORTX Therapeutics's growth, margins, and balance sheet.

A net income figure of $-3.9M for XRTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Materials average is about $18B. Explore the charts below for those layers of context.

After noting XRTX's net income ($-3.9M), review year-over-year change from $-1.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.